Redeye reviews the Sprint Bioscience case following a change of analyst and provide a more in-depth take on the company’s recent VADA deal. We believe upcoming triggers relating to Vps34 and VADA, in particular, bode well for the share price development. We adjust our base case to SEK3.4 (SEK1.1).